Omnicell reiterates Q1, FY25 guidance

On Wednesday, Omnicell (OMCL) reiterated guidance for Q1 and FY25 after announcing that CFO Nchacha Etta will be stepping down. Omnicell previously forecast 2025 adjusted EPS $1.65-$1.85 and revenue $1.105B-$1.55B. Analysts currently expect EPS of $1.78 on revenue of $1.14B. The company also previously forecast Q1 adjusted EPS 15c-25c on revenue of $255M-$265M. The current consensus for EPS is 21c and $260.21M for revenue. “”As we progress through 2025, we remain focused on successfully executing on our strategic priorities and driving long-term revenue growth while striving to deliver the innovation and expertise that should help our customers achieve enhanced clinical and operational outcomes, as they seek to move closer to the industry-defined vision of the Autonomous Pharmacy,” Chairman, President, and CEO Randall Lipps said. Shares of Omnicell are down about 1% in premarket trading.